Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions

L. Knoedler, J. Dean, F. Diatta, N. Thompson, S. Knoedler, R. Rhys, K. Sherwani, T. Ettl, S. Mayer, F. Falkner, K. Kilian, AC. Panayi, J. Iske, AF. Safi, SG. Tullius, S. Haykal, B. Pomahac, M. Kauke-Navarro

. 2024 ; 15 (-) : 1372862. [pub] 20240408

Language English Country Switzerland

Document type Journal Article, Review, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc25000348

Balancing the immune response after solid organ transplantation (SOT) and vascularized composite allotransplantation (VCA) remains an ongoing clinical challenge. While immunosuppressants can effectively reduce acute rejection rates following transplant surgery, some patients still experience recurrent acute rejection episodes, which in turn may progress to chronic rejection. Furthermore, these immunosuppressive regimens are associated with an increased risk of malignancies and metabolic disorders. Despite significant advancements in the field, these IS related side effects persist as clinical hurdles, emphasizing the need for innovative therapeutic strategies to improve transplant survival and longevity. Cellular therapy, a novel therapeutic approach, has emerged as a potential pathway to promote immune tolerance while minimizing systemic side-effects of standard IS regiments. Various cell types, including chimeric antigen receptor T cells (CAR-T), mesenchymal stromal cells (MSCs), regulatory myeloid cells (RMCs) and regulatory T cells (Tregs), offer unique immunomodulatory properties that may help achieve improved outcomes in transplant patients. This review aims to elucidate the role of cellular therapies, particularly MSCs, T cells, Tregs, RMCs, macrophages, and dendritic cells in SOT and VCA. We explore the immunological features of each cell type, their capacity for immune regulation, and the prospective advantages and obstacles linked to their application in transplant patients. An in-depth outline of the current state of the technology may help SOT and VCA providers refine their perioperative treatment strategies while laying the foundation for further trials that investigate cellular therapeutics in transplantation surgery.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25000348
003      
CZ-PrNML
005      
20250107151818.0
007      
ta
008      
250107e20240408sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2024.1372862 $2 doi
035    __
$a (PubMed)38650942
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Knoedler, Leonard $u Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany $u Division of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, United States
245    10
$a Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions / $c L. Knoedler, J. Dean, F. Diatta, N. Thompson, S. Knoedler, R. Rhys, K. Sherwani, T. Ettl, S. Mayer, F. Falkner, K. Kilian, AC. Panayi, J. Iske, AF. Safi, SG. Tullius, S. Haykal, B. Pomahac, M. Kauke-Navarro
520    9_
$a Balancing the immune response after solid organ transplantation (SOT) and vascularized composite allotransplantation (VCA) remains an ongoing clinical challenge. While immunosuppressants can effectively reduce acute rejection rates following transplant surgery, some patients still experience recurrent acute rejection episodes, which in turn may progress to chronic rejection. Furthermore, these immunosuppressive regimens are associated with an increased risk of malignancies and metabolic disorders. Despite significant advancements in the field, these IS related side effects persist as clinical hurdles, emphasizing the need for innovative therapeutic strategies to improve transplant survival and longevity. Cellular therapy, a novel therapeutic approach, has emerged as a potential pathway to promote immune tolerance while minimizing systemic side-effects of standard IS regiments. Various cell types, including chimeric antigen receptor T cells (CAR-T), mesenchymal stromal cells (MSCs), regulatory myeloid cells (RMCs) and regulatory T cells (Tregs), offer unique immunomodulatory properties that may help achieve improved outcomes in transplant patients. This review aims to elucidate the role of cellular therapies, particularly MSCs, T cells, Tregs, RMCs, macrophages, and dendritic cells in SOT and VCA. We explore the immunological features of each cell type, their capacity for immune regulation, and the prospective advantages and obstacles linked to their application in transplant patients. An in-depth outline of the current state of the technology may help SOT and VCA providers refine their perioperative treatment strategies while laying the foundation for further trials that investigate cellular therapeutics in transplantation surgery.
650    _2
$a lidé $7 D006801
650    12
$a transplantace orgánů $x škodlivé účinky $7 D016377
650    _2
$a zvířata $7 D000818
650    _2
$a buněčná a tkáňová terapie $x metody $7 D064987
650    _2
$a rejekce štěpu $x imunologie $x prevence a kontrola $7 D006084
650    _2
$a imunomodulace $7 D056747
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dean, Jillian $u School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States
700    1_
$a Diatta, Fortunay $u Division of Plastic Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, United States
700    1_
$a Thompson, Noelle $u University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States
700    1_
$a Knoedler, Samuel $u Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany
700    1_
$a Rhys, Richmond $u Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany
700    1_
$a Sherwani, Khalil $u Department of Hand, Plastic and Reconstructive Surgery, Burn Center, Berufsgenossenschaft (BG) Trauma Center Ludwigshafen, University of Heidelberg, Ludwigshafen, Germany
700    1_
$a Ettl, Tobias $u Department of Dental, Oral and Maxillofacial Surgery, Regensburg, Germany
700    1_
$a Mayer, Simon $u University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States
700    1_
$a Falkner, Florian $u Department of Hand, Plastic and Reconstructive Surgery, Burn Center, Berufsgenossenschaft (BG) Trauma Center Ludwigshafen, University of Heidelberg, Ludwigshafen, Germany
700    1_
$a Kilian, Katja $u Department of Hand, Plastic and Reconstructive Surgery, Burn Center, Berufsgenossenschaft (BG) Trauma Center Ludwigshafen, University of Heidelberg, Ludwigshafen, Germany
700    1_
$a Panayi, Adriana C $u Department of Hand, Plastic and Reconstructive Surgery, Burn Center, Berufsgenossenschaft (BG) Trauma Center Ludwigshafen, University of Heidelberg, Ludwigshafen, Germany
700    1_
$a Iske, Jasper $u Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité, Berlin, Germany $u Charité Universitätsmedizin Berlin, Berlin, Germany
700    1_
$a Safi, Ali-Farid $u Faculty of Medicine, University of Bern, Bern, Switzerland $u Craniologicum, Center for Cranio-Maxillo-Facial Surgery, Bern, Switzerland
700    1_
$a Tullius, Stefan G $u Division of Transplant Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
700    1_
$a Haykal, Siba $u Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany
700    1_
$a Pomahač, Bohdan, $u Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany $d 1971- $7 xx0117402
700    1_
$a Kauke-Navarro, Martin $u Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 15 (20240408), s. 1372862
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38650942 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250107 $b ABA008
991    __
$a 20250107151814 $b ABA008
999    __
$a ok $b bmc $g 2245127 $s 1236348
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 15 $c - $d 1372862 $e 20240408 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20250107

Find record

Citation metrics

Logged in users only

Archiving options